Earnings were $2.12 per share, 1 percent higher than the previous year.
The dividend for the full year 2025 will be $3.20 per share, an increase of 3 percent compared to the previous year.
AstraZeneca - with the diabetes and heart failure medicine Farxiga and the cancer medicine Tagrisso as bestsellers - has over 94,000 employees, of which just over 8,000 are in Sweden - mainly in the Södertälje and Gothenburg areas.
